Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

The FDA has announced seven Class I recalls related to this issue. Customers are urged to destroy the devices immediately instead of returning them to the manufacturer. 

This represents the latest in a series of safety concerns associated with the Impella platform. The FDA said it is still reviewing the matter and will keep the public informed as new details become available. 

Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

Neil G. Bluhm, a billionaire philanthropist with deep ties to Chicago, has donated an additional $50 million to a high-volume facility that already bears his name.

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

For years, the ECG market was relatively static. According to a new report, however, things are rapidly changing. 

UnitedHealthcare now requires patients enrolled in certain Medicare Advantage plans to receive a PCP referral before seeing a cardiologist. On May 1, the insurer will start denying all claims that do not include the necessary referral. UnitedHealthcare argues that "stronger PCP engagement" is good for patient care, but many stakeholders disagree.

Cardiologist Nathaniel Lebowitz, MD, reviews the latest updates in lipoprotein(a) awareness, testing and drug development.